Literature DB >> 15338108

Effects of norfluoxetine on the action potential and transmembrane ion currents in canine ventricular cardiomyocytes.

János Magyar1, Norbert Szentandrássy, Tamás Bányász, Valéria Kecskeméti, Péter P Nánási.   

Abstract

Norfluoxetine is the most important active metabolite of the widely used antidepressant compound fluoxetine. Although the cellular electrophysiological actions of fluoxetine are well characterized in cardiac cells, little is known about the effects of its metabolite. In this study, therefore, the effects of norfluoxetine on action potential (AP) configuration and transmembrane ion currents were studied in isolated canine cardiomyocytes using the whole cell configuration of patch clamp techniques. Micromolar concentrations of norfluoxetine (1-10 microM) modified AP configuration: amplitude and duration of the AP and maximum velocity of depolarization were decreased in addition to depression of the plateau and elimination of the incisura of AP. Voltage clamp experiments revealed a concentration-dependent suppression of both L-type Ca(2+) current, I(Ca) (EC(50)=1.13+/-0.08 microM) and transient outward K(+) current, I(to) (EC(50)=1.19+/-0.17 microM) having Hill coefficients close to unity. The midpoint potential of the steady-state inactivation of I(Ca) was shifted from -20.9+/-0.75 mV to -27.7+/-1.35 mV by 3 microM norfluoxetine ( P<0.05, n=7). No such shift in the steady-state inactivation curve was observed in the case of I(to). Similarly, norfluoxetine caused no change in the steady-state current-voltage relationship of the membrane or in the density of the inward rectifier K(+) current, I(K1). All these effects of norfluoxetine developed rapidly and were fully reversible. Comparing present results with those obtained previously with fluoxetine, it can be concluded that norfluoxetine displays stronger suppression of cardiac ion channels than fluoxetine. Consequently, the majority of the cardiac side effects observed during fluoxetine treatment are likely to be attributed to its metabolite norfluoxetine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15338108     DOI: 10.1007/s00210-004-0954-1

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  39 in total

1.  Fluoxetine-induced cardiotoxicity with response to bicarbonate therapy.

Authors:  A Graudins; C Vossler; R Wang
Journal:  Am J Emerg Med       Date:  1997-09       Impact factor: 2.469

2.  Human cytochromes mediating N-demethylation of fluoxetine in vitro.

Authors:  L L von Moltke; D J Greenblatt; S X Duan; J Schmider; C E Wright; J S Harmatz; R I Shader
Journal:  Psychopharmacology (Berl)       Date:  1997-08       Impact factor: 4.530

3.  Heart block in a patient on propranolol and fluoxetine.

Authors:  W M Drake; G D Gordon
Journal:  Lancet       Date:  1994-02-12       Impact factor: 79.321

4.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches.

Authors:  O P Hamill; A Marty; E Neher; B Sakmann; F J Sigworth
Journal:  Pflugers Arch       Date:  1981-08       Impact factor: 3.657

5.  Role of norfluoxetine in the inhibition of desipramine metabolism and in the inhibition of serotonin uptake after fluoxetine administration to rats.

Authors:  R W Fuller; H D Snoddy
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1991-07

6.  Effects of norfluoxetine, the major metabolite of fluoxetine, on the cloned neuronal potassium channel Kv3.1.

Authors:  B H Choi; J S Choi; S H Yoon; D J Rhie; D S Min; Y H Jo; M S Kim; S J Hahn
Journal:  Neuropharmacology       Date:  2001-09       Impact factor: 5.250

7.  Tachycardia, orthostatic hypotension and profound weakness due to concomitant use of fluoxetine and nifedipine.

Authors:  T L Azaz-Livshits; H D Danenberg
Journal:  Pharmacopsychiatry       Date:  1997-11       Impact factor: 5.788

8.  Determination of the antidepressant fluoxetine and its metabolite norfluoxetine in serum by reversed-phase HPLC with ultraviolet detection.

Authors:  P J Orsulak; J T Kenney; J R Debus; G Crowley; P D Wittman
Journal:  Clin Chem       Date:  1988-09       Impact factor: 8.327

9.  Human brain fluoxetine concentrations.

Authors:  C N Karson; J E Newton; R Livingston; J B Jolly; T B Cooper; J Sprigg; R A Komoroski
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1993       Impact factor: 2.198

10.  Differential effects of fluoxetine enantiomers in mammalian neural and cardiac tissues.

Authors:  János Magyar; Zoltán Rusznák; Csaba Harasztosi; Agnes Körtvély; Pál Pacher; Tamás Bányász; Csaba Pankucsi; László Kovács; Géza Szûcs; Péter P Nánási; Valéria Kecskeméti
Journal:  Int J Mol Med       Date:  2003-04       Impact factor: 4.101

View more
  4 in total

1.  Frequency-dependent effects of omecamtiv mecarbil on cell shortening of isolated canine ventricular cardiomyocytes.

Authors:  Balázs Horváth; Norbert Szentandrássy; Roland Veress; János Almássy; János Magyar; Tamás Bányász; Attila Tóth; Zoltán Papp; Péter P Nánási
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-09-22       Impact factor: 3.000

2.  Effects of tacrolimus on action potential configuration and transmembrane ion currents in canine ventricular cells.

Authors:  László Szabó; Norbert Szentandrássy; Kornél Kistamás; Bence Hegyi; Ferenc Ruzsnavszky; Krisztina Váczi; Balázs Horváth; János Magyar; Tamás Bányász; Balázs Pál; Péter P Nánási
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-19       Impact factor: 3.000

3.  Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology.

Authors:  J C Hancox; J S Mitcheson
Journal:  Br J Pharmacol       Date:  2006-09-11       Impact factor: 8.739

4.  Omecamtiv mecarbil evokes diastolic dysfunction and leads to periodic electromechanical alternans.

Authors:  Gábor Á Fülöp; Attila Oláh; Tamas Csipo; Tamás Radovits; Attila Tóth; Árpád Kovács; Róbert Pórszász; Roland Veress; Balázs Horváth; László Nagy; Beáta Bódi; Miklós Fagyas; Solveig Lind Helgadottir; Viktor Bánhegyi; Béla Juhász; Mariann Bombicz; Daniel Priksz; Peter Nanasi; Béla Merkely; István Édes; Zoltán Csanádi; Zoltán Papp
Journal:  Basic Res Cardiol       Date:  2021-04-12       Impact factor: 17.165

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.